异烟肼耐药对结核治疗转归的影响:高结核与HIV负担地区的前瞻性多中心研究
在坦桑尼亚达累斯萨拉姆开展前瞻性多中心观察研究,纳入861例开始WHO推荐一线抗结核治疗的结核患者,其中250例(29.0%)合并HIV感染、23例(2.7%)存在异烟肼耐药。异烟肼耐药(RR=6.0;95%CI=1.9-18.7;P<0.01)和HIV感染(合并或不合并ART)是不良治疗转归的独立预测因素。
要点
- 异烟肼耐药使不良治疗转归风险显著升高(RR=6.0;95%CI=1.9-18.7;P<0.01)。
- HIV感染合并不良转归风险升高(RR=2.3;95%CI=1.0-5.2;P=0.05)。
- 早期实验室检测异烟肼耐药对结核治疗成功具有重要意义。
核心结论
- 背景异烟肼耐药和HIV感染均对结核治疗转归产生不利影响。
- 早期实验室检测异烟肼耐药对结核治疗成功至关重要。
- 建议开展研究评估背景异烟肼耐药对异烟肼预防治疗疗效的影响。
研究设计与样本
- 多中心前瞻性观察性研究,纳入坦桑尼亚达累斯萨拉姆开始WHO推荐一线抗结核治疗的861例结核患者。
主要发现
- 861例患者中250例(29.0%)合并HIV感染,23例(2.7%)存在异烟肼耐药。
- 异烟肼耐药是不良治疗转归的独立预测因素(RR=6.0;95%CI=1.9-18.7;P<0.01)。
- HIV感染合并ART者不良转归风险升高(RR=2.3;95%CI=1.0-5.2;P=0.05)。
- HIV感染未合并ART者不良转归风险升高(RR=3.1;95%CI=1.5-6.2;P<0.01)。
临床怎么用
- 对结核患者应早期进行异烟肼耐药检测以指导治疗决策。
- 对合并HIV感染的结核患者应关注治疗转归并评估ART状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The scale and impact of background isoniazid resistance in TB- and HIV-endemic countries requires definition to improve treatment success and guide the scale-up of isoniazid preventive therapy (IPT). We describe the effects of isoniazid resistance on TB treatment outcomes among patients with or without HIV infection in Dar es Salaam, Tanzania. METHODS: A multicentre, prospective observational study was conducted among TB patients commencing WHO-recommended first-line TB treatment. In multivariate analysis we ascertained the relationship between isoniazid resistance at presentation with a composite of poor treatment outcomes (death, failure or default from TB therapy). RESULTS: Of 861 patients, 250 (29.0%) were HIV infected and 23 (2.7%) had isoniazid resistance. Seven hundred and ninety-seven (92.6%) of the patients were successfully treated and 25 (2.9%) died. Isoniazid resistance [relative risk (RR) = 6.0; 95% CI = 1.9-18.7; P < 0.01] and HIV infection with (RR = 2.3; 95% CI = 1.0-5.2; P = 0.05) or without (RR = 3.1; 95% CI = 1.5-6.2; P < 0.01) ART were independent predictors of poor treatment outcomes. CONCLUSIONS: Background isoniazid resistance and HIV infection adversely affected TB treatment outcomes. Early laboratory detection of isoniazid resistance is important for successful TB therapy. Studies on the impact of background isoniazid resistance on the efficacy of isoniazid prophylaxis are recommended.
引用
- Nagu TJ, Aboud S, Matee MI, et al. Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study. J Antimicrob Chemother. 2017. PMID: 27999054. doi:10.1093/jac/dkw503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。